DISC-1459 not checked

Disc Medicine, Inc · RO4917838

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
3 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Erythropoietic Protoporphyria
Main trialPhase 2/3
“This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.”In the company’s words, NCT05883748 on ClinicalTrials.gov
Other names
Bitopertin · RO4917838

Other drugs for Erythropoietic Protoporphyria

All 2 drugs for Erythropoietic Protoporphyria

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2/3Enrolling by invitation Jun 2028 HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Phase 3Completed 8 Sep 2026 Study of Bitopertin in Participants With EPP or XLP (APOLLO)
Phase 2Completed 20 Feb 2024 Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow DISC-1459

Following is part of Solo: you see every change to DISC-1459 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in